While NFkB may seem like a clear therapeutic target to slow the progression of ESCC, the challenges are numerous given that inhibition of NFkB, a required component of innate immunity, can lead to long-term immunosuppression and toxicity25,76,77. Here, NFKB1 is linked to esophageal squamous cell carcinoma.